Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study

被引:2
|
作者
Yuan, Guosheng [1 ]
Li, Wenli [1 ]
Zang, Mengya [1 ]
Li, Rong [1 ]
Li, Qi [1 ]
Hu, Xiaoyun [1 ]
Zhang, Qi [1 ]
Huang, Wei [2 ]
Ruan, Jian [3 ]
Pang, Huajin [4 ]
Chen, Jinzhang [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res, Guangzhou 510515, Guangdong, Peoples R China
[2] Southern Med Univ, Shunde Hosp, Dept Oncol, Shunde 528300, Guangdong, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Div Vasc & Intervent Radiol, Guangzhou 510515, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; TACE; Immune checkpoint inhibitors; Tyrosine kinase inhibitors; Overall survival; MICROENVIRONMENT; BEVACIZUMAB; SORAFENIB; TACE;
D O I
10.1007/s12672-024-00917-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives To explore the efficacy and safety of Transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC). Methods 456 patients with HCC receiving either TACE in combination with ICIs and TKIs (combination group, n = 139) or TACE monotherapy (monotherapy group, n = 317) were included from Apr 2016 to Dec 2021 in this retrospective study. We employed propensity score matching (PSM), performed 1:2 optimal pair matching, to balance potential bias. Results The mean follow-up time is 24.7 months (95% CI 22.6-26.8) for matched patients as of March 2022. After matching, the combination group achieved longer OS and PFS (median OS:21.9 vs. 16.3 months, P = 0.022; median PFS: 8.3 vs. 5.1 months, P < 0.0001) than TACE monotherapy group. The combination group had better objective response rate (ORR) and disease control rate (DCR) (ORR: 52.5% vs. 32.8%, P < 0.001; DCR: 82.7% vs. 59.6%, P < 0.001). Subgroup analysis showed that patients who received "TKIs + ICIs" after the first TACE procedure (after TACE group) achieved longer OS than those before the first TACE procedure (before TACE group) (26.8 vs. 19.2 months, P = 0.011). Adverse events were consistent with previous studies of TACE-related trials. Conclusions TACE plus TKIs and ICIs appeared to deliver longer PFS and OS in HCC patients than TACE monotherapy. "TKIs + ICIs" co-treatment within 3 months after the first TACE procedure might be a better medication strategy.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis
    Zhang, Jin-Xing
    Hua, Hong-jin
    Cheng, Yuan
    Liu, Sheng
    Shi, Hai-Bin
    Zu, Qing-Quan
    ACADEMIC RADIOLOGY, 2024, 31 (04) : 1304 - 1311
  • [32] Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Hengyu Tian
    Chidan Wan
    World Journal of Surgical Oncology, 23 (1)
  • [33] Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
    Feng, Jin-Kai
    Liu, Zong-Han
    Fu, Zhi-Gang
    Chai, Zong-Tao
    Sun, Ju-Xian
    Wang, Kang
    Cheng, Yu-Qiang
    Zhu, Hong-Fei
    Xiang, Yan-Jun
    Zhou, Li-Ping
    Shi, Jie
    Guo, Wei-Xing
    Zhai, Jian
    Cheng, Shu-Qun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyosuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Nonomura, Norio
    Uemura, Motohide
    ANTICANCER RESEARCH, 2021, 41 (11) : 5811 - 5816
  • [35] Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2024, 13 (03) : 227 - 234
  • [36] Efficacy and safety of apatinib plus immune checkpoint inhibitors and transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma
    Wu, Jianfei
    Bai, Xuefeng
    Yu, Guodong
    Zhang, Quan
    Tian, Xixi
    Wang, Yuan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (07)
  • [37] Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
    Ju, Shuguang
    Zhou, Chen
    Yang, Chongtu
    Wang, Chaoyang
    Liu, Jiacheng
    Wang, Yingliang
    Huang, Songjiang
    Li, Tongqiang
    Chen, Yang
    Bai, Yaowei
    Yao, Wei
    Xiong, Bin
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [38] Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors
    Shen, Jiaming
    Wang, Xia
    Yang, Guangde
    Li, Li
    Fu, Juanjuan
    Xu, Wei
    Zhang, Qingqiao
    Pan, Xiucheng
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 207 - 217
  • [39] Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study
    Bai, Wei
    Wang, Yong Ji
    Zhao, Yan
    Qi, Xing Shun
    Yin, Zhan Xin
    He, Chuang Ye
    Li, Rui Jun
    Wu, Kai Chun
    Xia, Jie Lai
    Fan, Dai Ming
    Han, Guo Hong
    JOURNAL OF DIGESTIVE DISEASES, 2013, 14 (04) : 181 - 190
  • [40] Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study
    Huang, Hongwei
    Liao, Wei
    Zhang, Kaiyue
    Wang, Hao
    Cheng, Qi
    Mei, Bin
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 721 - 735